Alteration of dopamine release by rat caudate putamen tissues superfused with alpha 2-macroglobulin.
Monoamine-activated alpha-2-macroglobulin (alpha 2M) has been shown to decrease the dopamine concentrations in rat caudate putamen (CP) in vivo as well as inhibit choline acetyltransferase activities in the culture of basal forebrain neurons. In this study, we further investigated the effects of methylamine-activated alpha 2M (MA-alpha 2M) upon striatal dopaminergic function by determining whether a direct infusion of this glycoprotein will alter dopamine (DA) release in vitro from superfused CP tissue fragments. In experiment 1, an infusion of 2.8 microM MA-alpha 2M produced a statistically significant increase in DA release compared with control superfusions. In experiment 2, varying doses (0, 0.7, 1.4, 2.8, 4.1 microM) of MA-alpha 2M were tested for their capacity to alter DA release. Only the 2.8 microM dose of MA-alpha 2M was effective in producing a significant increase of DA release. In experiment 3, the normal form of alpha 2M (N-alpha 2M) at 2.8 microM was compared with the control superfusions. The infusion of N-alpha 2M produced an increase in DA release which was substantially lower than the DA increase induced by MA-alpha 2M, and not significantly different from that of the control superfusion. These results show that MA-alpha 2M, like some other neurotoxins, can markedly alter CP dopaminergic function as indicated by the acute increase in DA release following infusion of this glycoprotein, and these effects are exerted at a relatively narrow range of doses. Taken together, these data suggest that this glycoprotein, if allowed to accumulate in the central nervous system (CNS), may promote some neurodegenerative changes that can occur in disorders like Parkinson's disease.
Hu
Y Q
YQ
Department of Microbiology and Immunology, Notheastern Ohio Universities College of Medicine, Rootstown, USA.
Liu
B J
BJ
Dluzen
D E
DE
Koo
P H
PH
D000544:Alzheimer Disease / Q000378:metabolism; D000818:Animals; D002421:Caudate Nucleus / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D008297:Male; D008744:Methylamines / Q000494:pharmacology; D009414:Nerve Growth Factors / Q000502:physiology; D009498:Neurotoxins / Q000494:pharmacology*; D010300:Parkinson Disease / Q000378:metabolism; D010477:Perfusion; D011699:Putamen / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017475:Receptors, Nerve Growth Factor / Q000502:physiology; D013268:Stimulation, Chemical; D000511:alpha-Macroglobulins / Q000187:drug effects / Q000494:pharmacology* / Q000502:physiology
D008744:Methylamines; D009414:Nerve Growth Factors; D009498:Neurotoxins; D017475:Receptors, Nerve Growth Factor; D000511:alpha-Macroglobulins; C027451:methylamine; D004298:Dopamine